熱門資訊> 正文
世卫组织推荐吉利德每年两次的艾滋病毒预防药物Yeztugo
2025-07-14 23:22
- 希倫布蘭德(HI) 0
- WSP控股(WH) 0
- 吉利德科學(GILD) 0
- The World Health Organization has recommended Gilead Sciences' (NASDAQ:GILD) recently FDA-approved twice yearly HIV pre-exposure prophylaxis (PrEP) treatment Yeztugo (lenacapavir).
- "With just two doses per year, [Yeztugo] is a transformative step forward in protecting people at risk of HIV – particularly those who face challenges with daily adherence, stigma, or access to health care," the organization said in a press release.
- While WHO noted that access to Yeztugo is currently limited, it is urging "governments, donors and global health partners to begin rolling out [lenacapavir] immediately within national combination HIV prevention programmes – while collecting essential data on uptake, adherence and real-world impact."
More on Gilead Sciences
- Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats
- Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
- Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- Gilead sees Q2 EPS hit from IPR&D expenses
- Arcus says Gilead-partnered cancer drug won FDA orphan status
推薦文章
華盛早報丨TACO交易再現！特朗普閃電改口「解僱鮑威爾」；美國眾議院加密貨幣立法進程受阻
財報前瞻 | 特斯拉Q2營收料下滑10%！股價銷量雙殺下，馬斯克能否逆轉局勢？
美股機會日報 | 低於市場預期！美國6月PPI同比增長2.3%；特斯拉官宣Model Y L
華盛早報丨事關中美關税！美財長最新放風；「加密周」突發！多項加密貨幣法案遭眾議院否決
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
美股機會日報 | 6月CPI符合預期！英偉達盤前漲超4%，今夜有望再創新高
華盛早報丨突發！特朗普100%關税劍指俄羅斯，歐盟720億歐元反制美國商品；黃仁勛年內第三次來華，出席鏈博會
美股機會日報 | 史上首次！比特幣升破12萬美元；馬斯克：特斯拉年底會有「史詩級震撼」的演示
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
